Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | vitamin D (1,25- dihydroxyvitamin D3) receptor | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Mus musculus | transient receptor potential cation channel, subfamily C, member 4 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | steroid hormone receptor | vitamin D (1,25- dihydroxyvitamin D3) receptor | 427 aa | 416 aa | 24.5 % |
Echinococcus multilocularis | short transient receptor potential channel 6 | transient receptor potential cation channel, subfamily C, member 4 | 890 aa | 799 aa | 31.2 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | ubiquitin conjugating enzyme E2 N | 0.0601 | 0.9999 | 1 |
Echinococcus multilocularis | transient receptor potential gamma protein | 0.0117 | 0.0827 | 0.0758 |
Loa Loa (eye worm) | hypothetical protein | 0.0117 | 0.0827 | 0.0827 |
Echinococcus multilocularis | ubiquitin conjugating enzyme E2 N | 0.0601 | 0.9999 | 1 |
Schistosoma mansoni | transient receptor potential channel | 0.0117 | 0.0827 | 0.0758 |
Loa Loa (eye worm) | phosphotyrosine protein phosphatase | 0.0263 | 0.359 | 0.359 |
Echinococcus granulosus | transient receptor potential ion channel A | 0.0113 | 0.0753 | 0.0684 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0601 | 0.9999 | 0.9999 |
Mycobacterium ulcerans | phosphotyrosine protein phosphatase PtpA | 0.0263 | 0.359 | 0.5 |
Echinococcus granulosus | transient receptor potential gamma protein | 0.0117 | 0.0827 | 0.0758 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0601 | 0.9999 | 1 |
Leishmania major | ubiquitin-conjugating enzyme e2, putative | 0.0601 | 0.9999 | 0.5 |
Mycobacterium tuberculosis | Probable enoyl-CoA hydratase EchA14 (enoyl hydrase) (unsaturated acyl-CoA hydratase) (crotonase) | 0.0298 | 0.4254 | 1 |
Plasmodium vivax | ubiquitin-conjugating enzyme E2 N, putative | 0.0601 | 0.9999 | 0.5 |
Schistosoma mansoni | ubiquitin conjugating enzyme 13 | 0.0601 | 0.9999 | 1 |
Brugia malayi | Ubiquitin conjugating enzyme protein 13 | 0.0601 | 0.9999 | 1 |
Trypanosoma brucei | ubiquitin-protein ligase, putative | 0.0601 | 0.9999 | 1 |
Brugia malayi | ubiquitin conjugating enzyme protein 13 | 0.0601 | 0.9999 | 1 |
Plasmodium falciparum | ubiquitin-conjugating enzyme E2 N, putative | 0.0601 | 0.9999 | 0.5 |
Echinococcus multilocularis | transient receptor potential ion channel A | 0.0113 | 0.0753 | 0.0684 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0601 | 0.9999 | 1 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0601 | 0.9999 | 0.9999 |
Entamoeba histolytica | ubiquitin-conjugating enzyme family protein | 0.0601 | 0.9999 | 1 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0601 | 0.9999 | 1 |
Schistosoma mansoni | transient receptor potential channel 4 | 0.0117 | 0.0827 | 0.0758 |
Toxoplasma gondii | ubiquitin-conjugating enzyme subfamily protein | 0.0601 | 0.9999 | 0.5 |
Trichomonas vaginalis | Sialidase-1 precursor, putative | 0.0601 | 1 | 1 |
Giardia lamblia | Low molecular weight protein-tyrosine-phosphatase | 0.0263 | 0.359 | 0.5 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0601 | 0.9999 | 1 |
Onchocerca volvulus | 0.0263 | 0.359 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | 0.668 uM | PUBCHEM_BIOASSAY: Confirmation dose response assay for compounds that activate transient receptor potential cation channel C4 (TRPC4). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2237, AID2259] | ChEMBL. | No reference |
EC50 (functional) | > 92.425 uM | PUBCHEM_BIOASSAY: Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRD1 homodimerization. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504326, AID504355, AID504692, AID504904, AID504905] | ChEMBL. | No reference |
EC50 (functional) | > 92.425 uM | PUBCHEM_BIOASSAY: Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based high throughput dose response assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504326, AID504355, AID504692, AID504904, AID504905] | ChEMBL. | No reference |
EC50 (functional) | > 92.425 uM | PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.2213 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 29.9349 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.